Valeant Pharmaceuticals International, Inc -- Moody's: Valeant's new Allergan bid raises financial leverage

New York, June 02, 2014 -- Moody's Investors Service commented that the most recently revised offer by Valeant Pharmaceuticals International, Inc. ("Valeant") to acquire Allergan, Inc. ("Allergan") would raise Valeant's financial leverage relative to the earlier offers, but that the proposed acquisition would still be credit positive for Valeant. Valeant is rated Ba3 with a developing outlook, and there is currently no impact on the ratings from the revised bid. Moody's notes, however, that the increasing amount of financial leverage in Valeant's bid reduces the degree of any upward pressure in Valeant's ratings if a deal is finalized.

Vollständigen Artikel bei Moodys lesen